

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Antonio FACCHIANO et al.

Confirmation No. 3449

Serial No. 10/077,746

GROUP 1653

Filed February 20, 2002

Examiner Sheridan Snedden

PEPTIDE INHIBITING PLATELET DERIVED GROWTH FACTOR (PDGF-BB) AND FIBROBLAST GROWTH FACTOR (bFGF) ACTIVITY

RECEIVED
DEC 0 1 2003
TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents Alexandria, VA 22313-1450

Sir:

Responsive to the restriction requirement set forth in the outstanding Official Action of October 29, 2003, applicants hereby provisionally elect Group I, claims 1-4, drawn to a peptide, with traverse.

It is respectfully submitted that Groups I to III are sufficiently closely related so that a search and examination of the entire application can be made without a serious burden on the Examiner. The present invention relates to the identification and synthesis of a peptide, derived from basic human fibroblast growth factor (bFGF). Claims 1 to 4 are drawn to the peptide. Claims 5 and 8 are directed to a method for inhibiting primary tumor growth in metastasis. Claims 6, 7, 9, 10 and 11 are directed to a method of preparing the pharmalogical

FACCHIANO et al. S.N. 10/077,746

compound of the present invention. Thus, the claims of the present invention are directed to subject matter in which a search and examination can be completed within a narrow discipline.

Thus, it is believed that Groups I through III are sufficiently closely related that a full search for either group would yield all prior relevant art to the other groups.

In light of the above discussion, therefore, it is believed that applicants are entitled to an action on the merits of all of claims 1 to 11, in their full scope, in the present application. Such action is accordingly respectfully requested.

Respectfully submitted,

YOUNG & THOMPSON

thilly a Dubois

Philip A. DuBois, Reg. No. 50,696

745 South 23rd Street Arlington, VA 22202 Telephone (703) 521-2297

November 26, 2003